Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355974 | 1.00 | CTSV (0.38) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL7558920 | 0.85 | CTSV (0.41) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL7704282 | 0.84 | CTSV (0.41) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL5063468 | 0.84 | CTSV (0.38) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL5685473 | 0.84 | CTSV (0.38) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL8241182 | 0.84 | CTSV (0.38) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL4813603 | 0.82 | AR (0.39) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL21684450 | 0.81 | CTSV (0.37) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL13705801 | 0.79 | CTSV (0.41) | CTSVCTSLCTSSCTSKAR | |
| SCHEMBL2754867 | 0.79 | AR (0.37) | CTSVCTSLCTSSCTSKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | CTSV 139/4885CTSL 287/4885CTSS 430/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | CTSV 165/4885CTSL 316/4885CTSS 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.